The effect of weight on exposure in hepatitis C: Peginterferon alfa-2b and peginterferon alfa-2a

被引：0

|

作者：

Silva, M

Cutler, D

Poo-Ramirez, JL

Wagner, F

Jackson, M

Cullen, C

机构：

来源：

GASTROENTEROLOGY | 2005年 / 128卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

收藏

页码：A723 / A723

页数：1

相关论文

共 50 条

[41] Comparison of peginterferon alfa-2a and alfa-2b for treatment of patients with chronic hepatitis C: a retrospective study using the Japanese Interferon Database
Sato, Izumi
Shimbo, Takuro
Kawasaki, Yohei
Masaki, Naohiko
DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 283 - 289
[42] The cost-effectiveness analysis of peginterferon alfa-2a and ribavirin versus interferon alfa-2b and ribavirin in chronic hepatitis C in Poland
Orlewska, E
Juszczyk, J
VALUE IN HEALTH, 2003, 6 (06) : 749 - 750
[43] A cost-utility analysis of peginterferon alfa-2a versus peginterferon alfa-2b as the initial treatment of hepatitis C from the perspective of the Veterans Affairs health care sysytem
Yeh, WS
Armstrong, EP
Skrepnek, GH
Malone, DC
VALUE IN HEALTH, 2006, 9 (03) : A158 - A158
[44] PATIENT REPORTED OUTCOMES AMONG CHRONIC HEPATITIS C PATIENTS RETREATED WITH PEGINTERFERON ALFA-2A/RIBAVIRIN AFTER NON-RESPONSE TO PEGINTERFERON ALFA-2B/RIBAVIRIN IN SPAIN
Olveira, A.
Rincon, D.
Diago, M.
Crespo, J.
Calleja, J. L.
Salmeron, J.
Andrade, R.
Romero, M.
VALUE IN HEALTH, 2011, 14 (07) : A282 - A282
[45] Interim analysis of the safety and efficacy of peginterferon alfa-2a plus ribavirin in chronic hepatitis C patients unable to tolerate or nonresponsive to treatment with peginterferon alfa-2b plus ribavirin
Rustgi, VK
Esposito, S
Freilich, B
Lopez-Talavera, JC
Lentz, E
Shiffman, ML
HEPATOLOGY, 2005, 42 (04) : 692A - 692A
[46] Pharmacokinetics of peginterferon ALFA-2A (40KD, PEGASYS) compared to peginterferon ALFA-2B (12KD, pegintron) in naive patients with chronic hepatitis C (CHC)
Bruno, R
Sacchi, P
Ciappina, V
Maffezzini, E
Patruno, SFA
Zocchetti, C
Filice, G
JOURNAL OF HEPATOLOGY, 2003, 38 : 129 - 130
[47] A cost utility analysis of peginterferon alfa-2a (40KD) versus peginterferon alfa-2b (12KD) for the treatment of chronic hepatitis C (CHC) in the UK
Latimer, NR
Lewis, GJ
VALUE IN HEALTH, 2005, 8 (06) : A58 - A58
[48] Peginterferon alfa-2b plus ribavirin for chronic hepatitis - Reply
Manns, MP
McHutchison, J
Koury, K
Albrecht, JK
LANCET, 2002, 359 (9302): : 264 - 264
[49] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C - Reply
Fried, MW
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (03): : 260 - 260
[50] Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C
Krawitt, EL
Ashikaga, T
Gordon, SR
Ferrentino, N
Ray, MA
Lidofsky, SD
JOURNAL OF HEPATOLOGY, 2005, 43 (02) : 243 - 249

← 1 2 3 4 5 →